Title:
IMP-3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME
Document Type and Number:
WIPO Patent Application WO/2014/188721
Kind Code:
A1
Abstract:
Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, chronic myelocytic leukemia, colon cancer, rectum cancer, esophageal cancer, gastric diffuse-type cancer, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), lymphoma, osteosarcoma, ovarian cancer, renal carcinoma, soft tissue tumor, testicular tumor, and HNC.
Inventors:
NISHIMURA YASUHARU (JP)
TOMITA YUSUKE (JP)
HIRAYAMA MASATOSHI (JP)
OSAWA RYUJI (JP)
TOMITA YUSUKE (JP)
HIRAYAMA MASATOSHI (JP)
OSAWA RYUJI (JP)
Application Number:
PCT/JP2014/002678
Publication Date:
November 27, 2014
Filing Date:
May 22, 2014
Export Citation:
Assignee:
ONCOTHERAPY SCIENCE INC (JP)
International Classes:
C12N15/09; A61K31/7088; A61K35/26; A61K38/00; A61K39/00; A61P35/00; C07K7/06; C07K7/08; C07K16/30; C12N1/21; C12N5/0783; C12N5/0784; C12N5/10
Other References:
TOMITA, Y. ET AL.: "Development of an Ideal and Potent Cancer Immunotherapy Designed by Consideration of HLA Polymorphism", MAJOR HISTOCOMPATIBILITY COMPLEX, vol. 20, no. 1, 26 March 2013 (2013-03-26), pages 45 - 56, XP055296689, Retrieved from the Internet
TOMITA, Y. ET AL.: "Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells", CANCER SCI., vol. 102, no. 1, 1 January 2011 (2011-01-01), pages 71 - 78, XP008153403, DOI: 10.1111/J.1349-7006.2010.01780.X
SUDA, T. ET AL.: "Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy", CANCER SCI., vol. 98, no. 11, 1 November 2007 (2007-11-01), pages 1803 - 1808, XP002476145, DOI: 10.1111/J.1349-7006.2007.00603.X
HIRAYAMA, M. ET AL.: "Identification of a single tumor antigen peptide that can induce both Th cells and CTLs and is derived from oncofetal antigen IMP-3", PROCEEDINGS OF THE 17TH ANNUAL MEETING OF JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY, 10 June 2013 (2013-06-10), pages 79, XP008182688
HIRAYAMA, M. ET AL.: "Identification of a promiscuous IMP-3-derived long peptide that can induce both Th cells and CTLs", PROCEEDINGS OF ANNUAL MEETING OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 42, 18 November 2013 (2013-11-18), pages 112, XP008182671
See also references of EP 3004346A4
TOMITA, Y. ET AL.: "Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells", CANCER SCI., vol. 102, no. 1, 1 January 2011 (2011-01-01), pages 71 - 78, XP008153403, DOI: 10.1111/J.1349-7006.2010.01780.X
SUDA, T. ET AL.: "Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy", CANCER SCI., vol. 98, no. 11, 1 November 2007 (2007-11-01), pages 1803 - 1808, XP002476145, DOI: 10.1111/J.1349-7006.2007.00603.X
HIRAYAMA, M. ET AL.: "Identification of a single tumor antigen peptide that can induce both Th cells and CTLs and is derived from oncofetal antigen IMP-3", PROCEEDINGS OF THE 17TH ANNUAL MEETING OF JAPANESE ASSOCIATION OF CANCER IMMUNOLOGY, 10 June 2013 (2013-06-10), pages 79, XP008182688
HIRAYAMA, M. ET AL.: "Identification of a promiscuous IMP-3-derived long peptide that can induce both Th cells and CTLs", PROCEEDINGS OF ANNUAL MEETING OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 42, 18 November 2013 (2013-11-18), pages 112, XP008182671
See also references of EP 3004346A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (1-1-1 Oroshi-machi, Tsuchiura-sh, Ibaraki 47, JP)
Download PDF: